Symbio Pharmaceuticals --- Joint research contract for PTLD extended by three years.

Symbio Pharmaceuticals <4582> announced on the 12th that it has extended its Cooperative Research and Development Agreement (CRADA) with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), under the National Institutes of Health (NIH), for an additional three years to develop treatments targeting post-transplant lymphoproliferative disorder (PTLD). The contract period has been extended until April 2029, and efforts will continue to advance the development of brincidofovir (BCV) as a treatment for EB virus-related diseases. The company entered into the CRADA with NIH/NIAID in April 2023.

Fisco JapanMay 13 09:42

Synbio Pharmaceuticals---In Q1, the company steadily advanced its efforts toward the development of BCV and the commercialization of IVD.

Shin Bio Pharmaceutical (<4582>) announced its consolidated financial results for the first quarter of the fiscal year ending December 2026 (January-March 2026) on the 7th. Revenue decreased by 11.6% year-over-year to 233 million yen, operating loss amounted to 2.341 billion yen (compared to a loss of 1.169 billion yen in the same period last year), ordinary loss reached 2.390 billion yen (versus a loss of 1.288 billion yen last year), and the net quarterly loss attributable to parent company shareholders was 2.401 billion yen (compared to a loss of 1.321 billion yen last year). The group aims to achieve a specific ratio between domestic and overseas sales revenue by 2030.

Fisco JapanMay 8 10:06

Shin Bio Pharmaceutical --- Shares fell following the announcement of the first-quarter performance for the fiscal year ending December 2026.

Shares declined. The announcement of first-quarter results for the fiscal year ending December 2014 triggered selling pressure, weighing on the stock. Due to the drug-price revision for Treaxin intravenous infusion and the increasing penetration of generic versions, revenue fell to JPY 233 million (down 11.6% year on year), operating loss widened to JPY 2.341 billion (compared with an operating loss of JPY 1.169 billion in the same period last year), and ordinary loss expanded to JPY 2.390 billion (versus an ordinary loss of JPY 1.288 billion a year earlier). Selling, general, and administrative expenses totaled JPY 2.513 billion, up 83% from the same period last year.

Fisco JapanMay 8 09:15

Despite downward pressure from weak market sentiment and declines in U.S. stocks, the downside is likely to remain firm.

[Emerging Market Stock Strategy] The emerging market is expected to trade lower today. On September 7 in the U.S. stock market, the Dow Jones Industrial Average fell by 313.62 points (-0.63%) to 49,596.97, ending a two-day rally. Iran has yet to respond to the peace proposal presented by the Trump administration, and fading hopes for an end to the conflict caused crude oil prices to stabilize at lower levels, weighing on stock prices. Selling pressure is likely to dominate today's emerging market following declines in major U.S. indices yesterday.

Fisco JapanMay 8 07:20

Sumitomo Forestry reports a 38.5% decrease in operating profit for the first quarter, totaling 23.9 billion yen.

Sumitomo Forestry <1911> reported its consolidated financial results for the first quarter of the fiscal year ending December 2026, with revenue increasing 4% year-on-year to 532.063 billion yen and operating income decreasing 38.5% to 23.905 billion yen. In the overseas housing business, the Australian single-family home market performed favorably, leading to an increase in unit sales. Meanwhile, in the U.S. single-family home market, high mortgage interest rates and economic uncertainty continued to result in a wait-and-see attitude among homebuyers, causing a decline in unit sales. [Positive evaluation] <979

Fisco JapanMay 8 05:02

SymBio Pharmaceuticals: Financial Results Brief for the First Quarter of Fiscal Year 2026 (December 2026) [Japanese GAAP] (Consolidated)

JPXMay 7 14:30 · Announcements